FoliuMed
FoliuMed is a vertically integrated medical cannabis company producing pharmaceutical-grade APIs, EU-GMP soft-gel capsules, and white-label products from Colombian cultivation through German manufacturing, serving B2B pharmaceutical companies and cannabis operators across 8 countries.
- Company typePrivate
- Founded2018
- HeadquartersBogotá, Colombia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What FoliuMed does
FoliuMed is a vertically integrated medical cannabis company founded in 2018, operating across Colombia, Germany, and Spain. The company controls the cannabis supply chain from cultivation through to pharmaceutical-grade manufacturing, producing active pharmaceutical ingredients (APIs) from a 16-hectare, 150-greenhouse cultivation site in Nemocón, Colombia (GACP-compliant) and processing them into finished dosage forms at an EU-GMP certified facility in Limburg, Germany, operating through a joint venture with Fidelio Healthcare. Its product portfolio includes cannabis APIs (CBD and THC), EU-GMP phytotherapeutics, soft-gel capsules (25mg CBD / 10mg THC), cosmeceuticals manufactured under GMP INVIMA in Colombia, white-label finished products, biomass extraction/tolling services, and R&D project management services.
The company serves a B2B customer base of pharmaceutical companies and cannabis operators across 8 countries on 3 continents, including Germany, Australia, the US, and South America. Named customers include Althea (soft-gel supply to Australia), Clever Leaves (bulk extract supplier), and Medisun and Veritas Pharma (cannabis concentrate LOIs). FoliuMed differentiates on cost efficiency (~10 cents per gram production cost vs. ~1 euro for Canadian indoor producers) and regulatory compliance (one of five producers worldwide manufacturing cannabis soft gels under EU-GMP), supported by a proprietary library of 70+ trademark-protected cannabis strains.
FoliuMed operates on a strictly B2B wholesale and contract manufacturing model, with revenue derived from API sales, white-label and contract manufacturing, bulk extract exports, and fee-for-service biomass processing and tolling. The company is 100% founder-financed, with approximately $10M USD of planned founder capital, and is exploring strategic investor fundraising. Distribution is handled through direct sales, the Fidelio Healthcare partnership for German distribution, and international export to regulated markets.
FoliuMed firmographics
Firmographics- Name
- FoliuMed
- Legal name
- FoliuMed
- Website
- https://foliumed.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- FoliuMed is a vertically integrated medical cannabis company producing pharmaceutical-grade APIs, EU-GMP soft-gel capsules, and white-label products from Colombian cultivation through German manufacturing, serving B2B pharmaceutical companies and cannabis operators across 8 countries.
- Ownership category
- akta.pro rank
Where FoliuMed is headquartered
LocationHeadquarters
- HQ city
- Bogotá
- HQ country
- Colombia
- HQ region
- Latin America
Offices4 records
Markets served
FoliuMed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Active Pharmaceutical Ingredients (APIs): Manufacture and sale of cannabis-derived APIs (CBD & THC) produced at extraction facilities in Colombia under GACP standards, sold to international pharmaceutical producers
- White Label Finished Products - Herbal Medicines & Phytotherapeutics: Manufactured at EU-GMP certified FoliuMed Pharma facility in Limburg, Germany. Includes herbal medicines and phytotherapeutics sold under white label to pharmaceutical companies.
- Cosmeceuticals: Cosmetics products manufactured under GMP INVIMA standards in Colombia, containing cannabinoid essential oils and THC formulations
- Biomass Processing/Tolling Services: Fee-for-service biomass processing including fee-for-service extraction, storage services, and tolling operations for third-party cannabis biomass
- Contract Manufacturing: EU-GMP contract manufacturing services for cannabis soft gel capsules and other finished pharmaceutical products for other cannabis companies
- Bulk Extracts Export: Sale of pharmaceutical-grade cannabis bulk extracts including full spectrum THC crude extract, standardized 20% CBD extract, and CBD isolate to international partners
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Pharmaceutical cannabis ingredients (B2B wholesale) |
Go-to-market motion4 records
Distribution channels4 records
Marketing channels12 records
FoliuMed product offering
Product offeringCore offering
FoliuMed manufactures and sells pharmaceutical-grade cannabis APIs (CBD and THC), full spectrum extracts, distillates, and isolates from its Colombian cultivation and extraction operations, and converts these into EU-GMP finished products — including precisely dosed soft gel capsules — at its German facility. It also offers tolling, white-label, and contract manufacturing services to other pharmaceutical companies and cannabis operators in regulated markets such as Germany, Australia, and the EU.
Product overview
FoliuMed is a vertically integrated medical cannabis company offering a portfolio of products and services across the supply chain. Core offerings include cannabis-derived Active Pharmaceutical Ingredients (APIs) with CBD and THC compounds, manufactured in Colombia under GACP standards and processed in Germany under EU-GMP. The company provides finished products including phytotherapeutics (EU-GMP certified in Germany) and cosmeceuticals (GMP INVIMA certified in Colombia), along with white label manufacturing services. Extraction services encompass biomass processing, full spectrum extracts, distillates, and isolates. R&D and project management services support oral dosage forms and regulatory compliance. The company also produces precise-dosing soft-gel capsules in Germany for prescription medicines, with sub-brands EQUILIBRIUM and TEGRA completing the portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- EQUILIBRIUM: Product brand referenced in product catalog
- FOLIUMED / TEGRA
- Roots
- Tao
Quantifiable outcome
- Less than half the cost of local production in Australia
- +4 more outcomes
Companies that use FoliuMed
Customer profileNamed customers4 records
Segments4 records
FoliuMed technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
FoliuMed partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, secondary and minor.
- Fidelio HealthcarecoreJoint venture partnership for EU-GMP pharmaceutical manufacturing and distribution in Germany. Fidelio operates GMP-certified production facility and controlled substance warehouse. Together with FoliuMed, one of five producers worldwide manufacturing cannabis soft gels for prescription medicines under EU-GMP. Fidelio subsidiary handles domestic German distribution of cannabis products.
- Clever LeavescoreOne-year international sales agreement for pharmaceutical-grade bulk cannabis extracts. Clever Leaves provides full spectrum THC crude extract, standardized 20% CBD extract, and CBD isolate. Materials shipped to FoliuMed's German operation for processing into soft gel capsules for Australia, Europe and Latin America.
- Sunset HoldingssecondaryStrategic alliance with US producer of Tao vape pens for product development and brand expertise. Part of portfolio of strategic alliances including Taproot for Roots and Sunset for Tao brands.
- Taproot HoldingscoreStrategic alliance with US cannabis producer for cultivation and manufacturing design expertise. Taproot designed FoliuMed's cultivation and manufacturing processes. Taproot operates GMP-ready facility in North Las Vegas with 7 dispensary licenses in Nevada. Brands include award-winning Roots vape pen (No.1 bestselling product on Leaflink). FoliuMed Chairman Shane Terry co-founded Taproot with Oliver Zugel.
- Trias Pharma GmbHsecondaryR&D partnership with Swiss pharmaceutical company experts in oral dosage forms. Collaboration for clinical study execution and regulatory consulting for pharmaceutical cannabis products.
- Howard Glicken (Advisory Board)minorFormer Clinton administration advisor on Latin American affairs, joins FoliuMed advisory board to expand institutional and business relationships in the Americas. Served as President's private sector delegate to inaugurations of Presidents of Argentina, Uruguay, Peru, Ecuador.
Scale indicators12 records
Recent moves7 records
Expansion highlights6 records
FoliuMed competitors and assessment
Company assessmentDirect peers
- Clever Leaves Holdings: Vertically integrated Colombian-origin cannabis producer with EU-GMP certified operations, supplying bulk cannabinoid extracts and APIs globally; directly comparable to FoliuMed's Colombian cultivation-to-extraction model and overlapping customer base (also a supplier to FoliuMed).
- MediPharm Labs: GMP-certified cannabis contract manufacturer specializing in white-label and bulk cannabinoid APIs for international pharma customers; directly comparable to FoliuMed's EU-GMP contract manufacturing and tolling services business.
- Khiron Life Sciences: Colombia-based medical cannabis company with cultivation in Latin America and EU-focused distribution of cannabinoid products; highly comparable to FoliuMed's LATAM-to-Europe strategy and pharmacy-channel go-to-market.
- Valens Company (The Valens Company): Cannabis contract manufacturer and white-label producer of cannabinoid extracts, distillates and formulated products for Canadian and international B2B customers; closely comparable to FoliuMed's CMO/white-label business.
Emerging players
- Brains Bioceutical: Producer of pharmaceutical-grade cannabinoid APIs and isolates supplied to researchers and pharma; comparable to FoliuMed's API business but at smaller scale.
Broad incumbents
- OrganiGram Holdings: Canadian cannabis producer with EU-GMP-certified medical cannabis products distributed in Germany and other markets; comparable wholesale supplier of pharmaceutical-grade cannabis ingredients.
- Jazz Pharmaceuticals (GW Pharmaceuticals): Owns the leading EU-GMP cannabinoid prescription medicine (Sativex/Epidiolex) and operates one of the few large-scale EU-GMP cannabis API facilities; sets the benchmark FoliuMed is targeting as a prescription-grade cannabinoid supplier.
- Aurora Cannabis: Large Canadian cannabis producer with EU-GMP medical cannabis products sold in Germany and other European markets; competes with FoliuMed's EU-GMP soft-gel and APIs in the same European prescription channels.
- Canopy Growth Corporation: Global cannabis company with medical cannabis brands and EU operations; broad incumbent that FoliuMed competes with in pharmacy-channel cannabinoid supply.
- Tilray Brands: Global cannabis leader with EU-GMP certified pharmaceutical operations, branded medical cannabis across Germany and Australia, and large-scale cultivation; competes with FoliuMed in pharmaceutical-grade supply and pharmacy distribution at much greater scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key highlights7 records
Customer concentration
FoliuMed social profiles
Digital presenceFoliuMed compliance and trust
Trust signalCompliance4 records
FoliuMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
FoliuMed leadership team
Management profileNumber of profiles
FoliuMed subsidiaries and ownership
Company hierarchySubsidiaries2 records
FoliuMed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FoliuMed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FoliuMed
What does FoliuMed do?
FoliuMed manufactures and sells pharmaceutical-grade cannabis APIs (CBD and THC), full spectrum extracts, distillates, and isolates from its Colombian cultivation and extraction operations, and converts these into EU-GMP finished products — including precisely dosed soft gel capsules — at its German facility. It also offers tolling, white-label, and contract manufacturing services to other pharmaceutical companies and cannabis operators in regulated markets such as Germany, Australia, and the EU.
Is FoliuMed a public or private company?
FoliuMed is a private company. It is currently operating.
When was FoliuMed founded?
FoliuMed was founded in 2018. It employs 11 to 50 people.
Where is FoliuMed based?
FoliuMed is headquartered in Bogotá, Colombia, in the Latin America region.
How does FoliuMed make money?
Six revenue lines are on record. Active Pharmaceutical Ingredients (APIs) is the primary driver. The others are white Label Finished Products - Herbal Medicines & Phytotherapeutics, cosmeceuticals, biomass Processing/Tolling Services, contract Manufacturing and bulk Extracts Export.
Who are FoliuMed's main competitors?
Direct peers on record are Clever Leaves Holdings, MediPharm Labs, Khiron Life Sciences and Valens Company (The Valens Company). Brains Bioceutical is listed as an emerging player. Broad incumbents are OrganiGram Holdings, Jazz Pharmaceuticals (GW Pharmaceuticals), Aurora Cannabis, Canopy Growth Corporation and Tilray Brands.
Does FoliuMed have an API?
No public API is recorded for FoliuMed.